NICE recommends Sprinraza for 5q spinal muscular atrophy
The recommendation is for infants, children and adults with 5q spinal muscular atrophy and will be available through a scheme known as a Managed Access Agreement.
Read Moreby Anna Smith | May 15, 2019 | News | 0
The recommendation is for infants, children and adults with 5q spinal muscular atrophy and will be available through a scheme known as a Managed Access Agreement.
Read Moreby Selina McKee | May 8, 2018 | News | 0
A new treatment option for the very rare condition infantile onset 5q spinal muscular atrophy (type I SMA) is among five medicines that have been endorsed by Scottish cost regulators for use on the NHS.
Read Moreby Selina McKee | Jun 2, 2017 | News | 0
EU regulators have issued clearance for the first therapy to treat spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.
Read Moreby Selina McKee | Jan 4, 2017 | News | 0
US regulators recently approved the first therapy to treat spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
